Genmab — Februar 2016
-
no harm, no foul - hjertet hopper bare lidt, når der er tale om udsættelse af regnskab. Det er sjældent gode nyheder...
-
Så vidt jeg kan se af alle analyikerrapporterne forventer de ca. 175-225 i daratumumab royalty i 2016
-
Guider de under 175 tror jeg de skuffer markedet. Guider de over 225 tror jeg markedet bliver positivt
-
gå ind op hjemmesiden under investor relations

-
Kan ikke få øje på investor relations nogen steder ,, hvor skal jeg lede??
-
Ja helt som forventet og fint
-
De forventer 250-300 mio. $ i Darzalex salg af J&J. Det er sq et godt første år...
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind